JP2010508369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010508369A5 JP2010508369A5 JP2009535610A JP2009535610A JP2010508369A5 JP 2010508369 A5 JP2010508369 A5 JP 2010508369A5 JP 2009535610 A JP2009535610 A JP 2009535610A JP 2009535610 A JP2009535610 A JP 2009535610A JP 2010508369 A5 JP2010508369 A5 JP 2010508369A5
- Authority
- JP
- Japan
- Prior art keywords
- fgfr4
- agent
- hyperproliferative disease
- use according
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 230000003463 hyperproliferative effect Effects 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 26
- 229940125408 FGFR4 inhibitor Drugs 0.000 claims description 19
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims description 18
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 230000006907 apoptotic process Effects 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 101150082429 FGFR4 gene Proteins 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000000824 cytostatic agent Substances 0.000 claims description 3
- 230000001085 cytostatic effect Effects 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000003042 antagnostic effect Effects 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 230000001640 apoptogenic effect Effects 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 102000055699 human FGFR4 Human genes 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 230000001817 pituitary effect Effects 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 description 6
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000683 nonmetastatic effect Effects 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical class OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- 101150008012 Bcl2l1 gene Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- JHIATKDBEBOOCO-HSBXUTMMSA-N zve62lie63 Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@H](COC(N)=O)[C@@]1(O)[C@H]3N(C)[C@H]3CN12 JHIATKDBEBOOCO-HSBXUTMMSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06022946.5 | 2006-11-03 | ||
| EP20060022946 EP1918376A1 (en) | 2006-11-03 | 2006-11-03 | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| PCT/EP2007/009533 WO2008052798A2 (en) | 2006-11-03 | 2007-11-02 | Fgfr4 promotes cancer cell resistance in response to chemotherapeutic drugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013126819A Division JP2013224308A (ja) | 2006-11-03 | 2013-06-17 | Ｆｇｆｒ４は化学療法薬剤に対する応答において癌細胞の抵抗性を促進する |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010508369A JP2010508369A (ja) | 2010-03-18 |
| JP2010508369A5 true JP2010508369A5 (enExample) | 2010-12-24 |
| JP5349320B2 JP5349320B2 (ja) | 2013-11-20 |
Family
ID=37837027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535610A Expired - Fee Related JP5349320B2 (ja) | 2006-11-03 | 2007-11-02 | Ｆｇｆｒ４は化学療法薬剤に対する応答において癌細胞の抵抗性を促進する |
| JP2013126819A Pending JP2013224308A (ja) | 2006-11-03 | 2013-06-17 | Ｆｇｆｒ４は化学療法薬剤に対する応答において癌細胞の抵抗性を促進する |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013126819A Pending JP2013224308A (ja) | 2006-11-03 | 2013-06-17 | Ｆｇｆｒ４は化学療法薬剤に対する応答において癌細胞の抵抗性を促進する |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100143386A1 (enExample) |
| EP (2) | EP1918376A1 (enExample) |
| JP (2) | JP5349320B2 (enExample) |
| AU (1) | AU2007315213B2 (enExample) |
| CA (1) | CA2668027C (enExample) |
| WO (1) | WO2008052798A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009046141A2 (en) | 2007-10-01 | 2009-04-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
| US8216783B2 (en) | 2008-04-14 | 2012-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors |
| FR2933702A1 (fr) * | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
| EP2169071A1 (en) * | 2008-09-29 | 2010-03-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Rodent cancer model for human FGFR4 Arg388 polymorphism |
| WO2012138975A1 (en) * | 2011-04-07 | 2012-10-11 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
| CA2839437A1 (en) * | 2011-06-16 | 2012-12-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
| EP2723391B1 (en) | 2011-06-24 | 2018-06-13 | University of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
| DE102011116613A1 (de) * | 2011-10-20 | 2013-04-25 | Atlas Elektronik Gmbh | Unbemanntes Unterwasserfahrzeug und Verfahren zum Lokalisieren und Untersuchen eines am Gewässergrund eines Gewässers angeordenten Objekts sowie System mit dem unbemannten Unterwasserfahrzeug |
| JP2015071566A (ja) * | 2013-10-03 | 2015-04-16 | 住友ベークライト株式会社 | Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物 |
| CN110354128A (zh) | 2013-10-18 | 2019-10-22 | 卫材R&D管理有限公司 | 嘧啶fgfr4抑制剂 |
| MX367723B (es) | 2013-10-25 | 2019-09-03 | Novartis Ag | Compuestos de anillos fusionados bicíclicos derivados de piridilo como inhibidores de fgfr4. |
| TW201612518A (en) * | 2014-01-17 | 2016-04-01 | Sanofi Sa | Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody |
| US20170107578A1 (en) * | 2014-03-21 | 2017-04-20 | The Translational Genomics Research Institute | Compositions, methods and kits for characterizing and screening for small cell ovarian carcinoma |
| LT3198033T (lt) * | 2014-09-26 | 2022-05-10 | Janssen Pharmaceutica Nv | Fgfr mutantinių genų rinkinių panaudojimas identifikuojant vėžiu sergančius pacientus, kurie reaguos į gydymą fgfr inhibitoriumi |
| EP3200786B1 (en) | 2014-10-03 | 2019-08-28 | Novartis AG | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| RU2017134379A (ru) | 2015-03-25 | 2019-04-03 | Новартис Аг | Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 |
| CA2982562C (en) | 2015-04-14 | 2023-06-13 | Eisai R&D Management Co., Ltd. | Crystalline fgfr4 inhibitor compound and uses thereof |
| JP7372740B2 (ja) | 2016-05-10 | 2023-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ |
| IL264950B2 (en) * | 2016-08-23 | 2024-01-01 | Eisai R&D Man Co Ltd | Combined treatments for the treatment of malignant liver cell carcinoma |
| WO2018055503A1 (en) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combination comprising a pd-1 antagonist and an fgfr4 inhibitor |
| ES2934341T3 (es) | 2016-11-02 | 2023-02-21 | Novartis Ag | Combinaciones de inhibidores de FGFR4 y secuestrantes de ácidos biliares |
| EP3444275A1 (en) | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Monoclonal antibody anti-fgfr4 |
| CA3102334A1 (en) * | 2018-06-15 | 2019-12-19 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
| CN114763573A (zh) * | 2021-01-12 | 2022-07-19 | 浙江省肿瘤医院 | Fgf19扩增作为预测fgfr抑制剂在食管鳞癌中敏感性的生物标志物及其潜在应用 |
| CN114736966A (zh) * | 2022-05-07 | 2022-07-12 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 逆转乳腺癌耐药性的组合制剂及标志物应用 |
| EP4509142A1 (en) | 2023-08-16 | 2025-02-19 | Ona Therapeutics S.L. | Fgfr4 as target in cancer treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19802377A1 (de) * | 1998-01-22 | 1999-08-19 | Max Planck Gesellschaft | Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs |
| EP1206234A4 (en) * | 1999-06-03 | 2005-06-01 | Jessie L S Au | METHODS AND COMPOSITIONS FOR MODULATING PROLIFERATION AND CELL DEATH |
| ES2363765T3 (es) * | 2002-01-31 | 2011-08-16 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Agonistas de fgfr. |
| CA2550245A1 (en) * | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| US20090247604A1 (en) * | 2004-02-05 | 2009-10-01 | Intradigm Corporation | RNAi Therapeutics for Treatment of Eye Neovascularization Diseases |
| TWI388568B (zh) * | 2006-02-10 | 2013-03-11 | Genentech Inc | 抗ｆｇｆ１９抗體及其使用方法 |
-
2006
- 2006-11-03 EP EP20060022946 patent/EP1918376A1/en not_active Ceased
-
2007
- 2007-11-02 EP EP07819556A patent/EP2092066A2/en not_active Ceased
- 2007-11-02 US US12/513,413 patent/US20100143386A1/en not_active Abandoned
- 2007-11-02 JP JP2009535610A patent/JP5349320B2/ja not_active Expired - Fee Related
- 2007-11-02 AU AU2007315213A patent/AU2007315213B2/en not_active Ceased
- 2007-11-02 WO PCT/EP2007/009533 patent/WO2008052798A2/en not_active Ceased
- 2007-11-02 CA CA2668027A patent/CA2668027C/en active Active
-
2013
- 2013-06-17 JP JP2013126819A patent/JP2013224308A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010508369A5 (enExample) | ||
| Stein et al. | Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration | |
| JP5349320B2 (ja) | Ｆｇｆｒ４は化学療法薬剤に対する応答において癌細胞の抵抗性を促進する | |
| Miyamoto et al. | Molecular pathways: cachexia signaling—a targeted approach to cancer treatment | |
| Reardon et al. | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma | |
| Isambert et al. | Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors | |
| JP2019151652A (ja) | Ｈｅｄｇｅｈｏｇ経路阻害剤を用いた増殖障害の処置および予後モニタリングの方法 | |
| Nikolaou et al. | The role of neurotensin and its receptors in non-gastrointestinal cancers: A review | |
| Tao et al. | Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinoma | |
| Zhou et al. | Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors | |
| Rahim et al. | The role of interleukin-6 in malignant mesothelioma | |
| Rivera-Valentin et al. | Bone sarcomas in pediatrics: progress in our understanding of tumor biology and implications for therapy | |
| JP2024075639A (ja) | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 | |
| EP2225262B1 (en) | Peptides specific for hepatocellular carcinoma cells and applications thereof | |
| JP7132848B2 (ja) | 癌の治療のための合理的併用療法 | |
| Asif et al. | Role of ATP-binding cassette transporter proteins in CNS tumors: Resistance-based perspectives and clinical updates | |
| Pishvaian et al. | A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy | |
| Udvorková et al. | Antibody-drug conjugates as a novel therapeutic modality to treat recurrent refractory germ cell tumors | |
| Takano et al. | Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth | |
| WO2024188978A1 (en) | Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer | |
| KR20190064562A (ko) | Mena 단백질 이소형 키나제를 표적화하는 항암 요법을 위한 방법 및 조성물 | |
| JP7239181B2 (ja) | 癌治療のための生物製剤 | |
| JP7145374B2 (ja) | インビボでの切断可能連結部分によって抗マトリプターゼ抗体にコンジュゲートされた化学療法剤を用いる腫瘍細胞の標的化 | |
| US20180207111A1 (en) | Immunotherapy for casr-expressing cancer (e.g. neuroblastoma) | |
| JP2024509887A (ja) | Ｅｐ３００分解剤および神経芽細胞腫におけるその使用 |